Mirataz Transdermal Ointment 5gm Tube
In StockPrescription Required
SKU: *V*MWI112952-H
$53.06
1 Count • tube / $53.06
Quantity
PRESCRIPTION REQUIRED:
This product requires a valid prescription for shipment, please note that HealthWarehouse may not accept prescriptions faxed or emailed by patients.
CAUTION: US Federal law restricts this drug to use by or on the order of a licensed veterinarian.
DESCRIPTION:Mirataz (mirtazapine transdermal ointment) is a white to off-white ointment containing 2% (w/w) of mirtazapine suitable for transdermal (topical) administration. Mirataz contains the following inactive ingredients: Polyethylene Glycol (PEG) 400, PEG 3350, Diethylene Glycol Monoethyl Ether, PEG-8 Caprylic/Capric Glycerides, Oleyl Alcohol, Butylated Hydroxytoluene, Dimethicone, and Dry Flo TS.
USES:Mirataz is indicated for body weight gain in cats with a history of weight loss.
WARNINGS:HUMAN WARNINGS: Not for human use. Keep out of reach of children. Wear disposable gloves when handling or applying Mirataz to prevent accidental topical exposure. After application, dispose of used gloves and wash hands with soap and water. After application, care should be taken that people or other animals in the household do not come in contact with the treated cat for 2 hours because mirtazapine can be absorbed transdermally and orally. However, negligible residues are present at the application site and the body of the cat at 2 hours after dosing. In case of accidental skin exposure, wash thoroughly with soap and warm water. In case of accidental eye exposure, flush eyes with water. If skin or eye irritation occurs seek medical attention. In case of accidental ingestion, or if skin or eye irritation occurs, seek medical attention.
PRECAUTIONS:Do not administer orally or to the eye. Use with caution in cats with hepatic disease. Mirtazapine may cause elevated serum liver enzymes (See Animal Safety). Use with caution in cats with kidney disease. Kidney disease may cause reduced clearance of mirtazapine which may result in higher drug exposure. Upon discontinuation of Mirataz, it is important to monitor the cat's food intake. Food intake may lessen after discontinuation of mirtazapine transdermal ointment. If food intake diminishes dramatically (>75%) for several days, or if the cat stops eating for more than 48 hours, reevaluate the cat. Mirataz has not been evaluated in cats < 2 kg or less than 6 months of age. The safe use of Mirataz has not been evaluated in cats that are intended for breeding, pregnant, or lactating cats. To report suspected adverse events, for technical assistance or to obtain a copy of the SDS, contact Dechra at (866) 933-2472. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/reportanimalae
STORAGE CONDITIONS:Store below 25°C (77°F). Multi-use tube. Discard within 30 days of first use..